Chemours (CC) is back in focus after a securities class action lawsuit accused the company of overstating demand for its Opteon line and issuing unreliable 2026 financial guidance, following reduced adjusted EBITDA expectations and disclosures of inventory oversupply.
Recent trading has been choppy for Chemours. The share price is up 3.65% over the last day and 2.85% across the past week, yet the 30 day share price return is down 7.75% and the 90 day move is down 19.10%. This suggests momentum has been fading even though the year to date share price return is 8.90% and the 1 year total shareholder return is down 1.59%. These moves have contributed to deeper 3 and 5 year total shareholder returns that are down 38.49% and 46.55% respectively as investors reassess risk following the lawsuit and the reduced adjusted EBITDA guidance.
Scan beyond Chemours and stress test your thesis against a curated 30 resilient stocks with low risk scores that may handle shocks like lawsuits and guidance cuts very differently.
Chemours now trades at a material gap to both analyst targets and one intrinsic value estimate. The real question is whether pricing reflects lawsuit risk or mispriced pessimism before looking at valuation detail.
Most Popular Narrative: 21% Undervalued
Chemours last closed at $13.34, while the most followed narrative anchors fair value at $16.90 using a 10.8% discount rate and a detailed build up of future earnings, cash flows, and PFAS related risks.
Chemours needs regulatory driven Opteon adoption, titanium dioxide cost advantages, and higher margin Performance Solutions exposure to data center and semiconductor demand to continue offsetting refrigerant destocking cycles, sulfur cost inflation, and PFAS related compliance costs.
See why 13 investors see Chemours as 21% undervalued.
Result: Fair Value of $16.90 (UNDERVALUED)
Still, unresolved PFAS liabilities and the risk that eased refrigerant regulations slow Opteon adoption could both challenge the Chemours undervaluation story that investors are leaning on.
Find out about the key risks to this Chemours narrative.
Next Steps
Sentiment around Chemours is clearly split, with legal and operational concerns on one side and potential upside drivers on the other. Move quickly and test the evidence for yourself with the full breakdown of 4 key rewards and 2 important warning signs
Looking for more Chemours sized investment ideas?
If Chemours has sharpened your focus on risk and reward, do not stop here. Broader opportunities can sharpen your judgment and prevent overconfidence in any single story.
- Spot potential value plays early by scanning a curated pool of quality candidates through the 29 high quality undervalued stocks.
- Strengthen your downside protection by filtering for resilient businesses using the list of solid balance sheet and fundamentals (24 results).
- Lock in a steadier stream of potential income by assessing payout-focused opportunities with the 5 dividend fortresses.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com